Related references
Note: Only part of the references are listed.被撤回的出版物: Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma (Retracted Article. See vol 15, pg 3240, 2009)
Christina K. Augustine et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Sumithra J. Mandrekar et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Genomic advances and their impact on clinical trial design
Sumithra J. Mandrekar et al.
GENOME MEDICINE (2009)
Toward the individualization of lung cancer therapy
Ariel Anguiano et al.
CANCER (2008)
Bayesian adaptive design for targeted therapy development in lung cancer - a step toward personalized medicine
Xian Zhou et al.
CLINICAL TRIALS (2008)
Utilization of genomic signatures to direct use of primary chemotherapy
Anil Potti et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
C. Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical application of the 70-gene profile: The MINDACT trial
Fatima Cardoso et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
被撤回的出版物: A genomic approach to identify molecular pathways associated with chemotherapy resistance (Retracted article. See vol. 11, pg. 1214, 2012)
Richard F. Riedel et al.
MOLECULAR CANCER THERAPEUTICS (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
被撤回的出版物: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities (Retracted Article. See vol 106, pg 6878, 2009)
Katherine S. Garman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Genomic strategies for personalized cancer therapy
Katherine S. Garman et al.
HUMAN MOLECULAR GENETICS (2007)
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors
Philip D. Bonomi et al.
CLINICAL CANCER RESEARCH (2007)
Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)
Jean-Yves Douillard et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Gefitinib (IRESSA) versus vinorelbine in chemonaive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study
Lucio Crino et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Sue-Jane Wang et al.
PHARMACEUTICAL STATISTICS (2007)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
E. A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Federico Cappuzzo et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Jan Bogaerts et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
Pasi A. Jaenne et al.
CLINICAL CANCER RESEARCH (2006)
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer diagnostics - Decision criteria for marker utilization in the clinic
SE Taube et al.
AMERICAN JOURNAL OF PHARMACOGENOMICS (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prognostic and predictive markers in cancer
BA Conley et al.
DISEASE MARKERS (2004)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies
FR Hirsch et al.
LUNG CANCER (2003)
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
H Elsaleh et al.
LANCET (2000)
Share Paper
